Trial Profile
Response Loss and Development of Neutralizing Antibodies During Long-Term Treatment with Romiplostim in Patients with Immune Thrombocytopenia
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2015
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 04 Aug 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.